Story perspectives

Daraxonrasib Doubles Survival, Earns FDA Fast-Track Status

4/23/2026

Summary

Revolution Medicines Doubles

Revolution Medicines reported daraxonrasib doubled survival, with 50 % living >13 months versus ~6 months on chemo.
In a trial, daraxonrasib alone yielded a 47 % response rate and 92 % disease-control in 38 patients.
Combined with chemotherapy, daraxonrasib produced a 58 % response rate in 40 patients and 84 % six-month progression-free survival.
The FDA granted fast-track status that could enable approval within weeks.
Revolution raised about $2.2 billion and is enrolling patients in a Phase 3 trial.

Summary

mRNA Vaccine Extends

Seven of eight patients who responded to a personalized mRNA vaccine—made by sequencing each tumor’s DNA and producing a custom dose—remain alive six years after treatment.
Dr. Vinod Balachandran said both killer and helper T cells are required for lasting immunity.
The Phase 1 trial of 16 early-stage pancreatic-cancer patients reported eight strong T-cell responders; a KRAS-targeted mRNA vaccine induced responses in about 85 % of early-trial participants.

1 of 2

Revolution Medicines Doubles

Revolution Medicines reported daraxonrasib doubled survival, with 50 % living >13 months versus ~6 months on chemo.
In a trial, daraxonrasib alone yielded a 47 % response rate and 92 % disease-control in 38 patients.
Combined with chemotherapy, daraxonrasib produced a 58 % response rate in 40 patients and 84 % six-month progression-free survival.
The FDA granted fast-track status that could enable approval within weeks.
Revolution raised about $2.2 billion and is enrolling patients in a Phase 3 trial.

1 / 2